Keyphrases
National Cohort Study
100%
Netherlands
100%
Leber Hereditary Optic Neuropathy
100%
Clinically Significant
100%
Randomized Controlled Trial
100%
Bevacizumab
100%
Clinical Outcomes
100%
Idebenone
100%
Age-related Macular Degeneration
100%
Treatment Outcome
100%
Optic Atrophy 1 (OPA1)
100%
Dominant Optic Atrophy
100%
WFS1
100%
Visual Acuity
75%
Visual Function
75%
Bevacizumab Treatment
50%
Ranibizumab
50%
DNA Encoding
25%
Effective Alternative
25%
Continuous Regimen
25%
Recovery Time
25%
Neural Tissue
25%
Retinal Ganglion Cell Layer
25%
Function Structure
25%
Ganglion Cell Complex
25%
Retrospective Survey
25%
Low Acuity
25%
Intravitreal Bevacizumab
25%
Start of Treatment
25%
Patients Included
25%
Vision Loss
25%
Treatment Duration
25%
Clinical Trials
25%
Clinical Examination
25%
Positive Responses
25%
Mitochondrial DNA
25%
Dutch
25%
Dutch Cohort
25%
Treatment Group
25%
Visual Acuity Change
25%
Retinal Thickness
25%
Optimal Injection
25%
Retinal Structure
25%
Acuity Score
25%
Injection Schedules
25%
Color Discrimination
25%
Central Foveal Thickness
25%
Retinal Nerve Fiber Layer
25%
Unusual Phenotype
14%
Phenotypic Change
14%
Pharmacology, Toxicology and Pharmaceutical Science
Cohort Study
100%
Age Related Macular Degeneration
100%
Idebenone
100%
Bevacizumab
100%
Leber Hereditary Optic Neuropathy
100%
Randomized Controlled Trial
100%
Autosomal Dominant Optic Atrophy
100%
Hearing Impairment
33%
Ranibizumab
28%
Mitochondrial DNA
25%
Congenital Malformation
16%
Wolfram Syndrome
16%
Optic Nerve Atrophy
16%
Clinical Trial
14%
Medicine and Dentistry
Leber Hereditary Optic Neuropathy
100%
Idebenone
100%
Cohort Analysis
100%
Autosomal Dominant Optic Atrophy
100%
Vision
75%
Visual Acuity
50%
Nerve Tissue
25%
Treatment Duration
25%
Retinal Ganglion Cell Layer
25%
Ganglion
25%
Retinal Nerve Fiber Layer
25%
Mitochondrial DNA
25%
Color Discrimination
25%
Clinical Examination
25%
Optic Nerve Atrophy
16%
Wolfram Syndrome
16%
Congenital Malformation
16%